Maxime Verhoeven

111 Effectiveness and safety of treat-to-target strategies over 5 years Table 2 (continued) Mean difference in HAQ scores between initial treatment strategy groups over 5 years and at the end of every year # Period Strategy comparisons Mean difference 95%CI of mean difference Over 5 years TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ - 0.05 0.03 - 0.08 - 0.22 to 0.11 - 0.14 to 0.20 - 0.25 to 0.08 1 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ - 0.10 - 0.04 - 0.06 - 0.26 to 0.05 - 0.20 to 0.11 - 0.21 to 0.09 2 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ - 0.09 - 0.03 - 0.06 - 0.25 to 0.06 - 0.19 to 0.12 - 0.21 to 0.09 3 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ - 0.05 0.02 - 0.08 - 0.23 to 0.12 - 0.15 to 0.20 - 0.25 to 0.09 4 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ - 0.05 0.02 - 0.08 - 0.23 to 0.12 - 0.15 to 0.20 - 0.25 to 0.09 5 TCZ+MTX vs. MTX TCZ vs. MTX TCZ+MTX vs. TCZ - 0.05 0.03 - 0.08 - 0.23 to 0.12 - 0.15 to 0.20 - 0.25 to 0.09 The treatment strategy groups are according to the initial randomization at start of U-Act-Early. All analyses were corrected for baseline DAS28 category (DAS28 <5.1 or ≥5.1) and centre. Outcomes are based on mixed model analyses with random intercept for repeated measurements, and fixed effects for treatment arm, visit-week, interaction visit-week*treatment arm. 1 = Cochran-Mantel-Haenszel test, 2 = linear regression, 3 = van Elteren test. # = no statistically significant differences between the groups. TCZ+MTX= tocilizumab + methotrexate initiation strategy group; TCZ= tocilizumab + placebo-methotrexate initiation strategy group; MTX= methotrexate + placebo-tocilizumab initiation strategy group; 95%CI= 95 percent confidence interval; SR= sustained remission; IQR= interquartile range; sDFR= sustained drug free remission; min= minimum; max= maximum; SvdH= Sharp van der Heijde score; JSN= joint space narrowing. 6